Abstract 1776P
Background
Patients with cancer may be at higher risk for a more severe form of COVID-19. The aim of this study was to evaluate the relationship between potential drug-drug interactions (PDDI) with hospital stays in COVID-19 cancer patients.
Methods
A retrospective study of all COVID-19 cancer patients was performed in the Hospital del Mar (Barcelona, Spain). Demographic and clinical data were obtained from electronic clinical records. Data on concomitant drugs at COVID-19 diagnosis were collected. Drug interactions were checked with Lexicomp database and classified by severity. Comparisons were analysed by Mann–Whitney U-test or Fisher’s exact test. P<0.05 statistically significant.
Results
Fifty patients were included, consisting of 30 women (60%), with a mean age of 70.1±12.7 years. The main cancer site was gastrointestinal 16 (32%), followed by breast 15 (30%), genitourinary 10 (20%), lung 6 (12%) and gynaecological 3 (6%). A total of 18 (36 %) patients had a history of prior treatment. Thirty-eight patients (76%) were discharged from hospital, 11 died (22%) and one (2%) was still in hospital. Four patients (8%) were admitted to ICU. The mean days of hospital stay was 15.8±10.4. The average number of concomitant drugs at COVID-19 diagnosis were 7±4.5 and PPDI were detected in 34 patients (68%). There was a mean (range) of 1 (1-4) major PDDI and 5.3 (1-18) moderate PPDI. The most common types of drugs involved in patients with hospital stays of ≥15 days were psychoanaleptics 31 (12.5 %), anxiolytic drugs 20 (8.0 %) and thiazides 15 (6.0 %), while in patients with hospital stay < 15 days were opioid drugs 14 (8.8 %), blood glucose lowering drugs, excluding insulins 13 (8.2 %) and psychoanaleptics 12 (7.6 %). Table: 1776P
| Hospital stay ≥ 15 days (N=24) | Hospital stay < 15 days (N=26) | P-value | |
| Age, years* | 71.5 (61.5-80) | 71.5 (58-84) | 0.749 |
| Female sex** | 14 (58.3) | 16 (61.5) | 1.000 |
| Prior treatment** | 15 (62.5) | 17 (65.4) | 1.000 |
| Concomitant drugs* | 7 (4-12) | 5.5 (3-8) | 0.267 |
| Potential DDI* | 4 (0.5-6.5) | 1.5 (0-6) | 0.231 |
| Major DDI* | 1.5 (0-1.5) | 1 (0-1) | 0.039 |
* median (Q1-Q3). **n (%)
Conclusions
Regardless of the number of hospitalisation days, most of the PDDI were related to drugs of the nervous system. Almost 70% of the patients presented PDDI. A longer hospital stay was associated with a greater number of severe PDDI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.